Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Share News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: Redx Surges On Potential Takeover Offer

Tue, 31st Dec 2019 10:34

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Tuesday.

----------

FTSE 100 - LOSERS

----------

HSBC, down 0.6%. The bank is planning to expand its exchange traded fund range in 2020 in order to revitalise its underperforming asset management business, the Financial Times reported. Nicholas Moreau, who was appointed chief executive of HSBC's asset management division in August, has devised a series of initiatives aimed at reinvigorating growth at a time when the London-listed bank is aggressively cutting costs, the FT said. In the first half of 2020, HSBC will launch eight ETF's employing environmental, social and governance metrics to tap into rising investor demand for ESG-focused strategies. HSBC also plans to develop a fixed income ETF platform in 2020 and to launch a range of precious metals tracker funds later in the year, the FT noted.

----------

FTSE 250 - WINNERS

----------

CLS Holdings, up 0.8%. The company said it will sell a portfolio of 19 regional offices in the UK for GBP65.0 million to Capital Partners, a Singaporean investment firm. The offices are located across the UK outside of the South East. Therefore the sale is in line with the FTSE 250-listed company's strategy of actively recycling its capital and focusing the UK portfolio on London and the South East, it said. Following the completion of the transaction, CLS will hold only two assets in the UK outside of the South East. "We continue to see significant opportunities for acquisitions across our core markets, and this transaction will allow us to recycle capital to capitalise on those opportunities," explained Chief Executive Fredrik Widlund.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

Redx Pharma, up 28%. The drug discovery and development company said it has been in discussions with Samuel Waksal, the founder of ImClone Systems and Kadmon Pharmaceuticals, about a possible cash takeover offer. Redx cautioned, however, there was as yet no "firm intention" to make an offer and there can be no certainty that the offer will be made. Waksal has until 1700 GMT on January 28 to make a firm offer, the company said. Redx also said it has been in discussions with shareholders and third-party healthcare specialist investors regarding longer-term funding of the company, in order to advance its medicines for cancer and fibrosis to the next stage trials. Therefore the company is asking shareholders for permission to agree to the capitalisation of a GBP2.5 million loan into ordinary shares at 5.25 pence per share. Back in June, the company had signed a loan agreement with Moulton Goodies - which has 18% stake in Redx - for a fixed-rate secured loan note facility of up to GBP2.5 million.

----------

Lansdowne Oil & Gas, up 18%. The exploration company said it has further extended the repayment date of its outstanding GBP1.0 million loan with LC Capital Master Fund, which had been due on Tuesday, to June 30 next year. The move follows a previous half-year extension, reported on June 28. Also at that time, the AIM-listed company had secured debt funding of GBP150,000 from LC Capital and GBP150,000 from Brandon Hill Capital by way of loan note. Lansdowne said that debt facility was expected to provide sufficient funds to carry the company through to the end of 2019. The company did not provide any further update regarding its cash position.

----------

OTHER MAIN MARKET AND AIM - LOSERS

----------

Bango, down 9.2%. The mobile commerce company reported continued growth in end-user spend, which is expected to achieve GBP1.1 billion in 2019, resulting in revenue growth for the year of 40% to "at least" GBP9.3 million. Adjusted earnings before interest, taxes, depreciation, and amortization for the full year is positive and in excess of GBP400,000. The year before, the company recorded an adjusted Ebitda loss of GBP870,000. However, this strong results will be still below market forecasts primarily due to a Customer Data Platform license and Marketplace supply deal not concluding in December as expected. These deals are now expected to close in early 2020, Bango said. The company said operating costs remain stable and in line with expectations. Bango said it continues to invest in research & development, growing the data monetisation business and boosting the Bango platform.

----------

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
5 Nov 2018 12:52

Redx Pharma Showcases Positive Preclinical Trial Results Of RXC004

LONDON (Alliance News) - Redx Pharma PLC on Monday reported a positive data from preclinical studies evaluating RXC004.The results were presented at the National Cancer Research Institute a

Read more
29 Oct 2018 14:50

Redx CEO Lisa Anson elected to Bioindustry Association board

(Sharecast News) - Drug development company Redx Pharma noted an announcement from the UK BioIndustry Association (BIA) on Monday that Lisa Anson had been elected to serve on the BIA board of directors.

Read more
24 Apr 2018 11:17

Redx Pharma Hires AstraZeneca UK President As Chief Executive

LONDON (Alliance News) - Shares jumped in Redx Pharma PLC on Tuesday as it announced the appointment of AstraZeneca PLC executive Lisa Anson as chief executive officer with effect on June in the I

Read more
22 Mar 2018 13:43

Redx Pharma Signs Agreement For Anti-Infective Programme With Deinove

LONDON (Alliance News) - Drug development company Redx Pharma PLC said Thursday that it has signed an option and licence agreement with chemicals company Deinove SAS for Novel

Read more
9 Feb 2017 14:21

RedX Pharma as it proposes discounted capital raising

(ShareCast News) - Shares in RedX Pharma are down almost 5% as it proposes raising £12m, before expenses, via a placing and subscription to advance its drugs pipeline. The proposed placing was of up to 20.5m shares, while the subscription was of 11.5m shares by Lanstead Capital, an institutional inv

Read more
30 Nov 2016 10:13

Redx Pharma To Present Pre-Clinical Profile Of RXC004 At Conference

Read more
20 Oct 2016 11:34

Redx Pharma identifies candidate for inhibitor programme

(ShareCast News) - Drug-development company Redx Pharma has identified a candidate for its reversible Bruton's tyrosine kinase (BTK) inhibitor programme. The compound, named RXC005, has the potential to treat the majority of patients suffering from chronic lymphocytic leukaemia (CLL), including tho

Read more
20 Oct 2016 08:33

Redx Pharma Selects Drug Candidate To Treat Leukaemia

Read more
27 Sep 2016 09:33

WINNERS & LOSERS SUMMARY: Wolseley Sold Amid Job Cuts, No Extra Payout

Read more
19 Sep 2016 08:13

Redx Pharma Sees Cancer Immunotherapy Promise For Porcupine Inhibitor

Read more
11 Sep 2016 15:25

Sunday share tips: Dunelm Group, Green REIT, Redx Pharma

(ShareCast News) - Buy shares in Dunelm Group, said the Sunday Times' Inside the City column. On Wednesday the home furnishings retailer is due to publish its first annual results under new chief executive John Browett. In the final three months of the year the FSTE 250 company - a sort of cut-price

Read more
24 May 2016 09:33

Redx Pharma Loss Widens But Notes Oncology Lead Progress

Read more
19 May 2016 10:17

Redx Pharma Welcomes Paper On Tackling Antimicrobial Resistance

Read more
9 May 2016 07:46

Redx Pharma Appoints David Lawrence Non-Executive Director

Read more
24 Mar 2016 14:08

Redx Pharma Raising GBP10.0 Million To Progress Its Pipeline (ALLISS)

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.